Wednesday, July 8, 2026

pharma · COVID-19 · Hepatitis C · AVIR

Atea Pharmaceuticals

Atea Pharmaceuticals is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker AVIR. Primary therapeutic focus areas include COVID-19, Hepatitis C, HEPATITIS C VIRUS CHRONIC INFECTION, Influen

225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US HQ
2014 Founded
57 Employees
Public company Type
AVIR · NYSE Ticker
Company details
Status
Public
HQ
225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
Founded
2014
Employees
57
Programs
37
Drugs
29
Patents
35
Clinical program

Ethinyl Estradioll/Levonorgestrel (EE/LNG)

Phase 1 · small molecule · Healthy Volunteer Study

Ethinyl Estradioll/Levonorgestrel (EE/LNG) for Healthy Volunteer Study is a Phase 1 program (small_molecule) at Atea Pharmaceuticals with 1 ClinicalTrials.gov record(s).

← All Atea Pharmaceuticals projects Phase 1 small molecule completed

Internal code AT-01B-012

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Atea Pharmaceuticals
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteer Study
Status
completed
Trials
1